Wednesday, July 8, 2026

pharma · Non-Hodgkin Lymphoma · Advanced Solid Tumors · ADCT

ADC Therapeutics

ADC Therapeutics clinical programs — 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Lausanne, Vaud, Switzerland, CH HQ
2011 Founded
272 Employees
Public company Type
ADCT · NYSE Ticker
Company details
Status
Public
HQ
Lausanne, Vaud, Switzerland, CH
Founded
2011
Employees
272
Programs
30
Drugs
15
Patents
22
Intelligence · Clinical Programs

ADC Therapeutics projects

14 ClinicalTrials.gov programs sponsored by ADC Therapeutics.

ADC Therapeutics has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ADCT-301

    ADC Therapeutics SA

    Acute Myeloid Leukemia

    phase 1 small molecule terminated

    1 trial
  2. ADCT-301

    ADC Therapeutics SA

    Head and Neck Cancer Squamous Cell Carcinoma

    phase 1 small molecule terminated

    1 trial
  3. ADCT-402

    ADC Therapeutics SA

    Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial
  4. ADCT-402

    ADC Therapeutics SA

    Non-Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial
  5. ADCT-402-105

    ADC Therapeutics SA

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial
  6. ADCT-502

    ADC Therapeutics SA

    Breast Cancer

    phase 1 small molecule terminated

    1 trial
  7. ADCT-601

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule terminated

    2 trials
  8. ADCT-901

    ADC Therapeutics SA

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial
  9. Camidanlumab tesirine

    ADC Therapeutics SA

    Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial
  10. Carmustine

    ADC Therapeutics SA

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 1 small molecule terminated

    1 trial
  11. Loncastuximab Tesirine

    ADC Therapeutics SA

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial
  12. Loncastuximab Tesirine and Acalabrutinib

    ADC Therapeutics SA

    Chronic Lymphocytic Leukemia

    phase 1 small molecule active

    1 trial
  13. Loncastuximab Tesirine and Durvalumab

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma

    phase 1 small molecule terminated

    1 trial
  14. Loncastuximab tesirine and rituximab (Lonca-R)

    ADC Therapeutics SA

    Central Nervous System Lymphoma

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does ADC Therapeutics have?

14 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.